Literature DB >> 23037493

Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Tuya Pal1, Susan T Vadaparampil.   

Abstract

BACKGROUND: It has become increasingly common to consider BRCA mutation status when determining optimal cancer risk management and treatment options in order to improve patient outcomes. Knowledge about the risk for hereditary cancer at or as close as possible to the time of diagnosis allows patients access to the most risk reduction options available.
METHODS: This paper illustrates the role of genetic risk assessment for hereditary breast cancer, using hereditary breast and ovarian cancer (HBOC) syndrome as a model due to germline mutations in the BRCA1 and BRCA2. Specifically, the value of genetic counseling and testing for HBOC across the cancer prevention and control continuum is outlined as it pertains to breast cancer.
RESULTS: In recognition of the importance of risk assessment for hereditary breast cancer, leading health professional organizations have developed specific guidelines and recommendations to providers for identification of women at increased risk for carrying a BRCA mutation.
CONCLUSIONS: Institutional efforts specific to genetic counseling and testing have resulted in the implementation of a model driven by physician recommendation as a referral system for high-risk breast cancer patients. Establishing an infrastructure to support research, education, and outreach initiatives focused on BRCA genetic counseling and testing will provide information that can improve the delivery of cancer genetics services.

Entities:  

Mesh:

Year:  2012        PMID: 23037493      PMCID: PMC4009502          DOI: 10.1177/107327481201900402

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  173 in total

1.  Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.

Authors:  Swati Biswas; Neelam Tankhiwale; Amanda Blackford; Angelica M Gutierrez Barrera; Kaylene Ready; Karen Lu; Christopher I Amos; Giovanni Parmigiani; Banu Arun
Journal:  Breast Cancer Res Treat       Date:  2012-01-21       Impact factor: 4.872

2.  Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance.

Authors:  Marlene H Frost; Jeffrey M Slezak; Nho V Tran; Constance I Williams; Joanne L Johnson; John E Woods; Paul M Petty; John H Donohue; Clive S Grant; Jeff A Sloan; Thomas A Sellers; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

3.  The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

Authors:  André Fedier; Rolf A Steiner; Viola A Schwarz; Lenka Lenherr; Urs Haller; Daniel Fink
Journal:  Int J Oncol       Date:  2003-05       Impact factor: 5.650

4.  Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.

Authors:  Steven A Narod; Jan Lubinski; Parviz Ghadirian; Henry T Lynch; Pal Moller; William D Foulkes; Barry Rosen; Charmaine Kim-Sing; Claudine Isaacs; Susan Domchek; Susan Domcheck; Ping Sun
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 6.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

7.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Authors:  Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

8.  Predictors of and satisfaction with bilateral prophylactic mastectomy.

Authors:  M E Stefanek; K J Helzlsouer; P M Wilcox; F Houn
Journal:  Prev Med       Date:  1995-07       Impact factor: 4.018

9.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

10.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

View more
  18 in total

1.  Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

Authors:  T Pal; J-H Lee; A Besharat; Z Thompson; A N A Monteiro; C Phelan; J M Lancaster; K Metcalfe; T A Sellers; S Vadaparampil; S A Narod
Journal:  Clin Genet       Date:  2013-03-21       Impact factor: 4.438

2.  Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.

Authors:  Anita Y Kinney; Rachel Howell; Rachel Ruckman; Jean A McDougall; Tawny W Boyce; Belinda Vicuña; Ji-Hyun Lee; Dolores D Guest; Randi Rycroft; Patricia A Valverde; Kristina M Gallegos; Angela Meisner; Charles L Wiggins; Antoinette Stroup; Lisa E Paddock; Scott T Walters
Journal:  Contemp Clin Trials       Date:  2018-09-18       Impact factor: 2.226

3.  Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.

Authors:  Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal
Journal:  Cancer       Date:  2017-02-09       Impact factor: 6.860

4.  Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.

Authors:  Ivana Antonucci; Martina Provenzano; Luca Sorino; Michela Balsamo; Gitana Maria Aceto; Pasquale Battista; David Euhus; Ettore Cianchetti; Patrizia Ballerini; Clara Natoli; Giandomenico Palka; Liborio Stuppia
Journal:  J Hum Genet       Date:  2016-12-08       Impact factor: 3.172

5.  Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland.

Authors:  Beata Smolarz; Magdalena Bryś; Ewa Forma; Marek Zadrożny; Jan Bieńkiewicz; Hanna Romanowicz
Journal:  Pathol Oncol Res       Date:  2017-12-05       Impact factor: 3.201

Review 6.  Implementing Precision Medicine: The Ethical Challenges.

Authors:  Diane M Korngiebel; Kenneth E Thummel; Wylie Burke
Journal:  Trends Pharmacol Sci       Date:  2016-12-07       Impact factor: 14.819

7.  A Framework for Pilot Testing Health Risk Video Narratives.

Authors:  Courtney Lynam Scherr; Kelli Nam; Bianca Augusto; Monica L Kasting; Meghan Caldwell; Marie Catherine Lee; Cathy D Meade; Tuya Pal; Gwendolyn P Quinn; Susan T Vadaparampil
Journal:  Health Commun       Date:  2019-04-18

8.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

Review 9.  Building risk-on-a-chip models to improve breast cancer risk assessment and prevention.

Authors:  Pierre-Alexandre Vidi; James F Leary; Sophie A Lelièvre
Journal:  Integr Biol (Camb)       Date:  2013-09       Impact factor: 2.192

10.  Strategies to enhance identification of hereditary breast cancer gene carriers.

Authors:  Sonya Reid; Lucy B Spalluto; Tuya Pal
Journal:  Expert Rev Mol Diagn       Date:  2020-09-11       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.